Stephen R Plymate
Overview
Explore the profile of Stephen R Plymate including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
8616
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Choi S, Ribeiro C, Wang Y, Loda M, Plymate S, Uo T
Biomolecules
. 2022 Nov;
12(11).
PMID: 36358940
There is an urgent need for exploring new actionable targets other than androgen receptor to improve outcome from lethal castration-resistant prostate cancer. Tumor metabolism has reemerged as a hallmark of...
12.
Sowalsky A, Plymate S, Haffner M, de Bono J, Sharp A
Eur Urol
. 2022 Aug;
82(5):e135-e136.
PMID: 36038450
No abstract available.
13.
Sowalsky A, Figueiredo I, Lis R, Coleman I, Gurel B, Bogdan D, et al.
Clin Cancer Res
. 2022 Jun;
28(16):3509-3525.
PMID: 35695870
Purpose: Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown clinical...
14.
Plymate S, Sprenger C, Haffner M
Cell Rep Med
. 2022 Mar;
3(2):100493.
PMID: 35243412
Metastatic prostate cancer remains uncurable. In this issue of , Rice et al. present an assessment of a compound (SU086) demonstrating activity in prostate cancer models through heat shock protein...
15.
Nyquist M, Ang L, Corella A, Coleman I, Meers M, Christiani A, et al.
J Clin Invest
. 2021 Jun;
131(12).
PMID: 34128479
No abstract available.
16.
Nyquist M, Ang L, Corella A, Coleman I, Meers M, Christiani A, et al.
J Clin Invest
. 2021 May;
131(10).
PMID: 33998604
Prostate cancer (PC) is driven by androgen receptor (AR) activity, a master regulator of prostate development and homeostasis. Frontline therapies for metastatic PC deprive the AR of the activating ligands...
17.
Paschalis A, Welti J, Neeb A, Yuan W, Figueiredo I, Pereira R, et al.
Cancer Res
. 2021 Apr;
81(4):1087-1100.
PMID: 33822745
Endocrine resistance (EnR) in advanced prostate cancer is fatal. EnR can be mediated by androgen receptor (AR) splice variants, with AR splice variant 7 (AR-V7) arguably the most clinically important...
18.
Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True L, et al.
Nat Commun
. 2021 Mar;
12(1):1426.
PMID: 33658518
Metastatic prostate cancer (mPC) comprises a spectrum of diverse phenotypes. However, the extent of inter- and intra-tumor heterogeneity is not established. Here we use digital spatial profiling (DSP) technology to...
19.
Sowalsky A, Sharp A, Trostel S, de Bono J, Plymate S
Cancer Treat Res Commun
. 2021 Jan;
28:100218.
PMID: 33516656
No abstract available.
20.
Uo T, Sprenger C, Plymate S
Front Oncol
. 2020 Nov;
10:580617.
PMID: 33163409
Metabolic reprogramming is associated with re/activation and antagonism of androgen receptor (AR) signaling that drives prostate cancer (PCa) progression to castration resistance, respectively. In particular, AR signaling influences the fates...